Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +1.00p +1.48% 68.50p 129,466 15:04:19
Bid Price Offer Price High Price Low Price Open Price
67.00p 70.00p 68.50p 67.00p 67.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.63 -8.93 -10.09 98.3

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
28/2/201912:22ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET11,356
28/8/201812:29ANGLE plc (AGL) One to Watch -
02/7/201812:06Still time to look at Angle (AGL)-
14/5/201809:44ANGLE (AGL) Strategic Move-

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-05-21 15:15:4667.4035,00023,590.00O
2019-05-21 15:15:4267.4025,00016,850.00O
2019-05-21 14:48:3567.4025,00016,850.00O
2019-05-21 13:14:5967.431,475994.52O
2019-05-21 12:11:2167.455,0003,372.50O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 67.50p.
Angle Plc has a 4 week average price of 66.50p and a 12 week average price of 51.50p.
The 1 year high share price is 78.50p while the 1 year low share price is currently 38p.
There are currently 143,486,522 shares in issue and the average daily traded volume is 112,062 shares. The market capitalisation of Angle Plc is £98,288,267.57.
alloa2003: I think the AGL share price is starting to reflect the potential value based on the risk that it may or may not be realised. For example if the potential value was £2 a share (based on profit, pe ratio, etc) and the chance of being successful was deemed 80% then you would expect the price to be much closer to £2. It is a form of arbitration with the share price reflecting the risk/reward factor compared to potential "fair value".
l0ngterm: Next two:2) What share price spectrum might arise if the trial demonstrates commercial data? I would hazard a guess anything between 200-500. However as Guardant is essentially data mining, and using analytics, and this seems to me where the long term value for Guardant is then.. what would a company pay to do the same with an approved front end CTC capture and harvest system? Possible over simplified this.. but you get my point.3) What share price spectrum might arise if the trial does not demonstrate commercial data?Depends on the data, if it proves CTCs can be captured, by the system and they then prove harvesting then what are the applications, especially if simulations, tests can be executed against cells going forward. We have had 19 papers expressing this so far.. this could actually be still be very lucrative. Just not immediately hazard a guess of say what 40p.. But all this also may be knocked sideways as essentially they are running the ovarian trial, if that is successful and proceeds to 200 patients then surely we will know sooner rather than later.
sicilian_kan: If the MBC trial is not, on the existing data (however confident one is) a nailed on certainty, surely the next questions are: 1) What is the best estimate probability of commercial data appearing in the MBC trial? 2) What share price spectrum might arise if the trial demonstrates commercial data? 3) What share price spectrum might arise if the trial does not demonstrate commercial data? Then an investment strategy can be formulated. There is far too little analysis of the actual MBC data that is available. There is also far too little analysis on here of the chance of success and on the share price gains and falls that might occur upon the MBC trial data being released.
alloa2003: There has been a sea change in the AGL share price of late, no highs then sharp reversals on announcements and no drifting on a lack of news. There is strong underlying demand for the shares which leads me to believe things are afoot behind the scenes.
sicilian_kan: At 70p, AGL's fully diluted market cap is £126m. 143,486,522 shares in issue, plus 20,555,806 options etc. = 164,042,328 shares fully diluted. This might see a 75p top before news, but quite frankly, the current share price is way overvalued given the risk involved, the laborious process involved (see youtube video) and the likely revenues from MBC. Given the hype around AGL, I think on good news 100-150p could be hit. On bad MBC results, we are looking at 10p-35p depending on how bad the results are. Results could also be mixed. So short term upside of 50-100%, short term downside potential of 50-80%. Chance of success, say 80-85%? I bear in mind that the ovarian trial was disappointing relative to the earlier study results. With significant downside possibility, I would expect a risk reward ratio of at least 3:1 to make this attractive. Fair price circa 50-55p? For those in at that level, it is definitely worth a hold, but I do not see buying in at the current share price as being in any way attractive.
jelenko: Probably an ISA scramble in my view. Given that news can come at any time on a few different fronts it makes sense to get the ISA loaded now, if funds allow. No doubt last weeks AACR will have raised the profile in the U.S. and that can only be good. I am holding these based on my own view that FDA is likely granted by end CY 2019 and if that is the case I feel the share price will at least treble from today's price. Not a bad return over a 9 month period. I plan to accumulate as many as I can on any weakness and just to provide occasional reassurance I keep tabs on EXAS share price on Nazdaq!!
semper vigilans: As usual a decent bit of research from a large, highly reputable organisation working in the right field, is not really recognised by the market. Whatever one thinks of false starts earlier, at some stage the build up of published, independent research must give the AGL share price a decent, upward shove?
alloa2003: Brexit is not helping sentiment but not the reason for AGL share price weakness. There is literally no interest in the stock at the moment - going to be news driven for some time to come until we see sales and profits. Might drift until it finds support.
alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off.
alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :)
Angle share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190522 05:44:25